SecBot SecBot

ARGX

ARGENX SE
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. P7· CIK 0001697862 Biotech & Drug Discovery
$950.95 −9.09 (−0.95%)
Nov 16 4:00 PM ET · prev $960.04
Market cap
$60.9B
Large cap
Consensus
Buy
88% Buy or better · 26 analysts
Median target
🔒 Subscribers only
1 year
+2.3%
from $929.61 · Nov 17
30 days
+15.2%
from $825.61
52-week range
$663.93–1,058.90
−10% from high · low Mar 20
Avg volume 20D
407.0K
Oct 22 spike 1.02M
Short interest
1.41M
≈2.3% of shares · +4.3%
Days to cover
3.4
at average volume
New fund stakes
8
Q2 2026 13F · 2 exits
Filing reports
19
analyzed by SecBot
Congress trades
3
disclosed
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 4 bullish · 2 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 8/10

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 46 added (8 new), 23 trimmed or exited. Largest new: Capital Research Global Investors $82.1M, Canada Pension Plan Investment Board $56.2M.

  • AnalystsBULLISH

    23 of 26 rate it Buy or better.

  • EstimatesFALLING

    Current-quarter EPS estimate $8.058 → $7.320 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +4.3% to 1.41M shares. 3.4 days to cover, ≈2.3% of shares.

  • TrendUPTREND

    3% above its 50-day average.

Who's buying

13F· Q2 2026
8
new positions
2
exits
$358.8M
in new stakes

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

26 analysts
Buy 88% rate it Buy or better
Strong Buy8Buy15Hold3Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 27, 2026Citigroup
MAINTAIN
MAINTAINBuy
Oct 23, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 23, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 23, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight

Earnings setup

Estimates
$7.32
EPS estimate, this quarter
−9%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$7.32$6.56–$8.08-16.5%$1.9B
Next Q$6.49$6.49–$6.49-26.6%$1.9B
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
9 drugs tracked · Drug pipeline →
Recent
Nov 12, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company")…
Nov 9, 2026
M&A
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
Amsterdam, the Netherlands, November 9, 2026, 07:00 CET, argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a…
Nov 7, 2026
Press release
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
November 7, 2026, 10:00 AM ET
Nov 5, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company")…
Nov 3, 2026
Press release
argenx to Present at Upcoming Investor Conferences
November 3, 2026

Short side

FINRA· Oct 30, 2026
1,412,594
shares short
+4.3%
vs prior settlement
3.4
days to cover
≈2.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Congressional trades
ARGX trades disclosed by members of Congress, with disclosure delay.
1 members · 3 buys / 0 sells
DateMemberType AmountDisclosed
Oct 27, 2026 Gilbert CisnerosDHouse ARGENX SE BUY $1K–$15K Nov 10, 2026 +14d
Oct 15, 2026 Gilbert CisnerosDHouse ARGENX SE BUY $1K–$15K Nov 10, 2026 +26d
Oct 14, 2026 Gilbert CisnerosDHouse ARGENX SE BUY $15K–$50K Nov 10, 2026 +27d

SecBot reports

19 filings · 4 press releases · 8 bullish · 0 bearish · 2 mixed · 9 neutral
All ARGX filing & press-release reports (23)